GlassScriptPhysician profile
Robin A Siefker
NPI 1730379272
$12,140.24
in general payments reported to CMS, 2019-2025
29 companies · $3,414 in 2025
The $3,414 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,222 · 2022: $1,757 · 2023: $2,179 · 2024: $2,568 · 2025: $3,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,161.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,541.26 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $1,393.10 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,201.29 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $989.77 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $940.66 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $874.48 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $774.44 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $751.19 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $688.62 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $566.79 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $485.99 | 2021-2025 | Trintellix |
| Indivior INC. | $336.20 | 2021-2025 | Sublocade, Perseris |
| Avanir Pharmaceuticals, INC. | $299.22 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $246.64 | 2021 | |
| Corium, LLC | $210.00 | 2022-2025 | Azstarys |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $189.63 | 2022-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $165.28 | 2021-2024 | Xelstrym |
| Tris Pharma INC | $91.17 | 2023-2025 | Dyanavel Xr |
| Harmony Biosciences LLC | $67.95 | 2023-2024 | Wakix |
| Braeburn INC. | $65.00 | 2023-2025 | Brixadi |
| Biogen, INC. | $57.04 | 2024-2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $51.91 | 2024-2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $41.05 | 2021 | |
| Merck Sharp & Dohme LLC | $26.25 | 2022-2023 | Belsomra |
| Collegium Pharmaceutical, INC. | $22.96 | 2025 | Jornay Pm |
| Noven Pharmaceuticals, INC. | $21.45 | 2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $15.00 | 2023 | Jornay Pm |
| Orexo US, INC. | $14.19 | 2022 | |
| Eisai INC. | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Siefker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.